Icagen

Pfizer acquires Icagen

Wednesday, July 20, 2011

Pfizer and Icagen have entered into a definitive merger agreement. Pfizer, which currently owns approximately 11% of Icagen’s fully diluted shares, will acquire the remaining 8.3 million shares at a price of $6 per share. The aggregate transaction value, including the value of the shares currently owned by Pfizer, is approximately $56 million.

[Read More]